Broader Market Sentiment and Risk Aversion: Global growth concerns and geopolitical instability (e.g., Middle East conflict, IMF downgrades) can lead investors to shun riskier growth stocks like clinical-stage biotech companies, impacting their valuations and ability to raise capital.

Cost of Capital and Funding Environment: As a clinical-stage biotech company, Arvinas relies on external funding for its extensive R&D. Rising interest rates or a tightening capital market environment can increase borrowing costs and make it harder to secure funding, which is crucial for advancing its drug pipeline.

Regulatory Developments and Clinical Trial Success: The biotechnology sector is profoundly influenced by regulatory approvals and successful clinical trial outcomes. Positive or negative news regarding FDA submissions (like for vepdegestrant) or phase trial results for pipeline candidates (e.g., ARV-102, ARV-806, ARV-393) are primary drivers of stock performance.